Nervous Disorder TRIZ Cases

ELISA assays measure phosphorylated Rubicon levels, resolving diagnostic accuracy limits in Parkinson's disease detection.

Admixing purified curcuminoid with ar-turmerone overcomes poor absorption and rapid metabolism to raise blood levels by up to 16-fold.

IRE-1α inhibitors block RNAse activity to relieve protein folding stress and prevent apoptosis in autoimmune diseases.

Immunoglobulin G converts harmful secondary injury into beneficial regeneration by balancing inflammatory mediators to preserve neurons.

Selective alpha 7 nicotinic acetylcholine receptor agonists treat fatigue while minimizing adverse effects through targeted receptor activation.

Screening method targets FLRT3 expression and transport to identify substances that suppress peripheral neuropathy pain.

3,5-bis(3,4-dihydroxyphenyl)-1,2,4-triazole disrupts beta-amyloid and alpha-synuclein fibril structures.

A metastin derivative encapsulated in a lactic acid-glycolic acid copolymer matrix provides controlled release kinetics.

Selected internal sites in the Fc domain allow precise covalent binding, resolving heterogeneity and activity loss from random coupling.

Engineered framework regions enable a humanized antibody to bind TGF-beta, resolving immunogenicity issues while maintaining therapeutic efficacy.

Biomarker analysis identifies inflammatory, metabolic, neurotrophic, and depressive endophenotypes to guide personalized cognitive loss treatment.

Nucleic acid nanoparticles traverse the blood-brain barrier via intranasal administration to deliver therapeutic cargo directly to the central nervous system.

An anhydrous delivery reservoir draws subcutaneous fluid to dissolve hydrophilic permeants, overcoming limited skin permeability for large molecules.

Evaluating epithelial to mesenchymal transition biomarkers guides IGF-1R inhibitor selection, preventing unnecessary toxic exposure in non-responsive patients.

Site-directed mutagenesis of CDR loops restores GITR binding affinity in humanized antibodies while reducing immunogenicity risks.

Mulberry extract delays peak glucose response to prevent nocturnal metabolic disruption and enhance slow-wave sleep.

Reducing cannabidiol dosage alongside everolimus minimizes adverse drug interactions while maintaining seizure control in tuberous sclerosis complex treatment.

Formula I compound upregulates neuroglobin and inhibits apoptosis, addressing the lack of therapies for SARS-CoV-2 neurological damage.

Quinoline derivatives modulate miR-124 expression, addressing safety and remission issues in inflammatory disease treatment.

Serum lipidomic analysis detects specific mass-to-charge ratios to identify Alzheimer's disease.

Antibodies recognize specific phospho-epitopes on tau protein to resolve the contradiction between therapeutic efficacy and recognition specificity.

Engineering 293TT cells with SV-40 large T antigen enables long-term Torque teno virus replication, resolving production reliability issues.

Insoluble salt particles buffer acidic polymer degradation products to prevent burst release and ensure reliable sustained drug delivery.

Calculating the ratio of soluble alpha-synuclein oligomers to total protein in cerebrospinal fluid enables pre-symptomatic diagnosis.

Mesoporous silica carriers release purmorphamine and retinoic acid to overcome hostile adult environments and ensure long-term stem cell survival.

Targeting c-src expression reduces alpha-synuclein denaturation, addressing the lack of cause elimination in current synucleinopathy treatments.

A targeted polypeptide delivers a non-cytotoxic protease to neuroendocrine tumor cells via receptor binding.

Phage display screening yields human NINJ-1 antibodies that eliminate mouse cross-reactivity while maintaining high binding affinity.

Met inhibitors down-regulate the MET receptor to counteract radiation-induced invasiveness and prevent tumor relapse.

Sideritis extracts replace synthetic stimulants by inhibiting dopamine reuptake, reducing side effects while improving attention and impulse control.

Specific LCDR and HCDR sequences in anti-IL-34 antibodies resolve low affinity issues by blocking IL-34 receptor interactions.

Small molecule compounds modulate FGF activity to enhance receptor binding, overcoming polypeptide complexity to improve stroke recovery.

Composite ingredients accelerate alcohol clearance to resolve ineffective reduction of blood alcohol concentration.

Optimized peptide vectors bind human LDLR receptors to transport therapeutic molecules across the blood-brain barrier.

Segmenting methionyl-tRNA synthetase reveals resectins with novel biological functions, bypassing the limitation of full-length sequence analysis.

Recombinant adeno-associated viral vectors cross the blood-brain barrier to restore glucose transporter 1 expression in endothelial cells.

Antipurinergic agents treat autism spectrum disorder by targeting purinergic signaling pathways to alleviate symptoms across diverse genetic backgrounds.

A pharmaceutical gel combines levodopa with enzyme inhibitors to increase drug bioavailability.

Modifying CCNY palmitoylation redirects synaptic localization to inhibit function and treat cognitive diseases.

Stable diazoxide sulfate and hydrochloride salts modify release kinetics to reduce adverse side effects like dyspepsia while maintaining therapeutic efficacy.

Phosphorylated U1-70K peptides selectively target autoreactive T cells, reducing anti-DNA antibodies and delaying glomerulonephritis onset.

PEGylated IGF-I variants extend circulation half-life through site-specific polymer attachment.

Sonogashira coupling synthesizes fluoropyridine oximes that cross the blood-brain barrier to restore enzyme activity against nerve agents.

Applying electromagnetic energy to transform gum base powder into cohesive chewing gum structures.